UNASSIGNED: Eyes with LSCD were randomized to two groups to undergo either autologous oral mucosal epithelial cell sheet (CAOMECS) combined with AM transplantation (A group) or AM transplantation alone (B group). Clinical outcome measures were corneal epithelium healing, best corrected visual acuity, symblepharon, corneal transparency, corneal neovascularization and ocular surface inflammation.
UNASSIGNED: The normal corneal epithelialization rate in group A (73.33%) was higher than that in group B (35.48%), and the average healing time was shorter (3.45 ±2.12 weeks vs. 4.64 ±1.63 weeks). The symblepharon in the above two groups was improved in the first 3 months after surgery, but after 6 months, part of the B group had recurrence. In improving corneal transparency, group A has obvious advantages. Corneal neovascularization (CNV) was improved to some extent in the first 3 months after surgery, but group A (1.47 ±0.64) was better than group B (1.94 ±0.85) after 6 months. Both groups can improve the inflammatory state to some extent.
UNASSIGNED: The transplantation of CAOMECS offers a viable and safe alternative in the reconstruction of a stable ocular surface. The effect is better than that of traditional AM transplantation, mainly in promoting corneal epithelialization, improving ocular surface structure, and reducing fiber and vascular infiltration.
■将患有LSCD的眼睛随机分为两组,分别进行自体口腔粘膜上皮细胞片(CAOMECS)联合AM移植(A组)或单独进行AM移植(B组)。临床结果测量为角膜上皮愈合,最佳矫正视力,symblepharon,角膜透明度,角膜新生血管形成和眼表炎症。
■A组正常角膜上皮形成率(73.33%)高于B组(35.48%),平均愈合时间较短(3.45±2.12周vs.4.64±1.63周)。上述两组患者在术后前3个月均有改善,但6个月后,B组部分复发。在提高角膜透明度方面,A组具有明显的优势。术后前3个月角膜新生血管(CNV)得到一定程度的改善,但6个月后A组(1.47±0.64)优于B组(1.94±0.85)。两组均可在一定程度上改善炎症状态。
■CAOMECS的移植为重建稳定的眼表提供了可行且安全的替代方案。效果优于传统的AM移植,主要是促进角膜上皮化,改善眼表结构,减少纤维和血管浸润.